Clinical trials: Patient Safety
Diabetes Mellitus
SEGUDIAB Study: Evaluation of Safety in the Diabetic Patients
The safety in the diabetic patient refer so much to the accuracy of the treatment and to the handling of the diabetic in security topics.
- Trial name
- SEGUDIAB (NCT01087541)
- Testing
- Educational program 6-hour standardized
- Where
- Spain
- Volunteers
- 6,830 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Acne Vulgaris
A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
- Trial name
- NCT01974141
- Testing
- Dapsone Gel, Dapsone Gel Vehicle
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,102 people
- Sponsor
- Almirall, S.A.
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell…
- Trial name
- NCT05267054
- Testing
- Ociperlimab, Tislelizumab, Rituximab
- Where
- 19 sites in China
- Volunteers
- 53 people
- Sponsor
- BeiGene
Major Depressive Disorder
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week…
- Trial name
- NCT00797966
- Testing
- OPC-34712, ADT
- Where
- 50 sites in United States
- Volunteers
- 850 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Neurobehavioral Disinhibition
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury…
- Trial name
- NCT03095066
- Testing
- AVP-786-28, AVP-786-42.63
- Where
- 54 sites in United States
- Volunteers
- 168 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Neoplasm Metastasis, Palliative Care
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
- Trial name
- NCT00545129
- Testing
- Tanezumab 10 mg IV
- Where
- 39 sites in United States, Austria and 11 more
- Volunteers
- 59 people
- Sponsor
- Pfizer
Idiopathic Pulmonary Fibrosis
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan) 10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- MUSIC (NCT00903331)
- Testing
- ACT-064992 (macitentan)
- Where
- 53 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Actelion
Rheumatoid Arthritis
A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)
This open-label, single arm, multicenter long-term extension study of WA19926 (NCT01007435) will evaluate the safety and efficacy of tocilizumab in participants with early, moderate to severe RA who have completed the 104-week…
- Trial name
- NCT01668966
- Testing
- Tocilizumab
- Where
- 6 sites in Brazil
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Juvenile Idiopathic Arthritis
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
- Trial name
- NCT01500551
- Testing
- Tofacitinib
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 302 people
- Sponsor
- Pfizer
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Skin Cancer
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Background: Melanoma antigen recognized by T-cells (MART-1) and gp100 are two genes found in melanoma cells. An experimental procedure developed for treating patients with advanced melanoma uses these genes and a type of virus to…
- Trial name
- NCT00923195
- Testing
- MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, NSCLC
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
The purpose of this study was to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab.
- Conditions
- Ovarian Cancer, NSCLC, ESCC, Solid Tumors
- Trial name
- NCT04939701
- Testing
- ASP0739
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Epilepsies, Partial
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of pregabalin in pediatric patients with partial onset seizures that are incompletely controlled on their current…
- Trial name
- NCT00437281
- Testing
- Pregabalin
- Where
- 18 sites in United States, Mexico and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phenylketonuria
Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
SYNB1934-CP-003 was designed as a 3-part, adaptive study consisting of a dose-escalating, open-label period (DEP; Part 1) of up to 15 weeks, followed by a 4-week, double-blind, placebo-controlled, randomized withdrawal period…
- Trial name
- SYNPHENY-3 (NCT05764239)
- Testing
- SYNB1934v1
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 35 people
- Sponsor
- Synlogic
Sepsis
Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure
The purpose of this study is to determine the effect of resatorvid on subjects with sepsis.
- Trial name
- NCT00633477
- Testing
- Resatorvid
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Takeda
Arginase I Deficiency, Hyperargininemia
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who…
- Trial name
- NCT03378531
- Testing
- AEB1102
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 14 people
- Sponsor
- Immedica Pharma AB
Ovarian Cancer, Triple-negative Breast Cancer
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in…
- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Trial name
- NCT03992131
- Testing
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- pharmaand GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.